Marcelo Westerlund Montera

Marcelo Westerlund Montera

Auto-generated profile, based on publicly available information

Marcelo Westerlund Montera

Hospital Pró-Cardíaco, Brasil

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 July 2022 in Arquivos Brasileiros de Cardiologia
Verified
Journal Article
Closed access
PDF file
MMMarcelo Westerlund Montera
Marcelo Westerlund Montera
FMFabiana Marcondes-Braga
Fabiana Marcondes-Braga
MSMarcus Vinícius Simões
Marcus Vinícius Simões
LMLídia Ana Zytynski Moura
Lídia Ana Zytynski Moura
FFFabio Fernandes
Fabio Fernandes
HSHeinz-Peter Schultheiss
Heinz-Peter Schultheiss
Sumário 1. Epidemiologia 149 2. Definição e Etiologia 150 […] Diretriz de Miocardites da Sociedade Brasileira de Cardiologia – 2022 Sumário 1. Epidemiologia 149 2. Definição e Etiologia 150 […] Diretriz de Miocardites da Sociedade Brasileira de Cardiologia – 2022

1 January 2024 in Arquivos Brasileiros de Cardiologia
Verified
Journal Article
Open access
PDF file
FFFabio Fernandes
Fabio Fernandes
MSMarcus V. Simões
Marcus V. Simões
ECEdileide de Barros Correia
Edileide de Barros Correia
FMFabiana Marcondes-Braga
Fabiana Marcondes-Braga
OCOtavio Rizzi Coelho-Filho
Otavio Rizzi Coelho-Filho
EMEvandro Tinoco Mesquita
Evandro Tinoco Mesquita
1. Introduction Scientific knowledge of hypertrophic cardiomyopathy (HCM) has significantly improved in the past decades. A better understanding of its pathogenesis, significant advances in the use of imaging methods, and the more common application of genetic analysis, in addition to a better characterization of the natural history of this myocardial disease, have profoundly reformulated its clinical and prognostic significance. Conversely, these processes were accompanied by the development of new medications addressing molecular mechanisms intrinsically linked to the pathophysiology and pathogenesis [...] 1. Introduction Scientific knowledge of hypertrophic cardiomyopathy (HCM) has significantly improved in the past decades. A better understanding of its pathogenesis, significant advances in the use of imaging methods, and the more common application of genetic analysis, in addition to a better characterization of the natural history of this myocardial disease, have profoundly reformulated its clinical and prognostic significance. Conversely, these processes were accompanied by the development of new medications addressing molecular mechanisms intrinsically linked to the pathophysiology and pathogenesis

1 January 2024 in Arquivos Brasileiros de Cardiologia
Verified
Journal Article
Open access
PDF file
FFFabio Fernandes
Fabio Fernandes
MSMarcus V. Simões
Marcus V. Simões
ECEdileide de Barros Correia
Edileide de Barros Correia
FMFabiana Marcondes-Braga
Fabiana Marcondes-Braga
OCOtavio Rizzi Coelho-Filho
Otavio Rizzi Coelho-Filho
EMEvandro Tinoco Mesquita
Evandro Tinoco Mesquita
1. Introdução O conhecimento médico científico sobre a cardiomiopatia hipertrófica (CMH) recebeu grande avanço nas últimas décadas. O melhor entendimento da sua patogênese, os avanços expressivos no emprego dos métodos de imagem e a aplicação mais corriqueira da análise genética, além da melhor caracterização da história natural dessa doença miocárdica, trouxeram uma profunda reformulação do seu significado clínico e prognóstico. Por outro lado, esses progressos foram acompanhados do desenvolvimento de novas drogas endereçando mecanismos moleculares intrinsecamente ligados à fisiopatogênese da [...] 1. Introdução O conhecimento médico científico sobre a cardiomiopatia hipertrófica (CMH) recebeu grande avanço nas últimas décadas. O melhor entendimento da sua patogênese, os avanços expressivos no emprego dos métodos de imagem e a aplicação mais corriqueira da análise genética, além da melhor caracterização da história natural dessa doença miocárdica, trouxeram uma profunda reformulação do seu significado clínico e prognóstico. Por outro lado, esses progressos foram acompanhados do desenvolvimento de novas drogas endereçando mecanismos moleculares intrinsecamente ligados à fisiopatogênese da

19 September 2023 in ABC Heart Failure & Cardiomyopathy
Verified
Journal Article
Open access
PDF file
MMMarcelo Westerlund Montera
Marcelo Westerlund Montera
Introduction Takotsubo Cardiomyopathy (CT), also known as stress-induced cardiomyopathy, is a reversible syndrome that usually presents as an acute coronary syndrome, especially in postmenopausal women. The pathophysiology involves multiple factors, including coronary vasospasm, microcirculation dysfunction, catecholaminergic aggression, and sympathetic hyperactivity. The diagnosis of the classic presentation is the presence of a segmental alteration in the form of ballooning or dyskinesia in the antero-septo-apical region of the left ventricle, associated with hyperdynamia of the basal segments, in the absence of obstructive [...] Introduction Takotsubo Cardiomyopathy (CT), also known as stress-induced cardiomyopathy, is a reversible syndrome that usually presents as an acute coronary syndrome, especially in postmenopausal women. The pathophysiology involves multiple factors, including coronary vasospasm, microcirculation dysfunction, catecholaminergic aggression, and sympathetic hyperactivity. The diagnosis of the classic presentation is the presence of a segmental alteration in the form of ballooning or dyskinesia in the antero-septo-apical region of the left ventricle, associated with hyperdynamia of the basal segments, in the absence of obstructive

7 October 2026 in Arquivos Brasileiros de Cardiologia
Verified
Journal Article
Open access
PDF file
FTFlavio Tarasoutchi
Flavio Tarasoutchi
JFJoao Ricardo Fernandes
Joao Ricardo Fernandes
VRVitor Emer Egypto Rosa
Vitor Emer Egypto Rosa
RSRoney Orismar Sampaio
Roney Orismar Sampaio
DSDiana Patricia Lamprea Sepulveda
Diana Patricia Lamprea Sepulveda
WEWilliam Antonio de Magalhães Esteves
William Antonio de Magalhães Esteves
Sumário […] Diretriz Brasileira de Valvopatias – 2026 Sumário […] Diretriz Brasileira de Valvopatias – 2026

10 December 2021 in ABC Heart Failure & Cardiomyopathy
Verified
Journal Article
Closed access
PDF file
MMMarcelo Westerlund Montera
Marcelo Westerlund Montera
In cardiac amyloidosis, amyloid infiltrate at the atrial level promotes atrial dilation and contractile dysfunction as well as a higher prevalence of atrial fibrillation which, when associated with ventricular diastolic and systolic dysfunction, favors blood stasis and the consequent development of intracardiac thrombosis (ICT) and cardioembolic events. In a study of 116 autopsies of patients with cardiac amyloidosis, conducted at the Mayo Clinic, the presence of ICT was demonstrated in 33% of hearts, with a significantly higher prevalence in patients [...] In cardiac amyloidosis, amyloid infiltrate at the atrial level promotes atrial dilation and contractile dysfunction as well as a higher prevalence of atrial fibrillation which, when associated with ventricular diastolic and systolic dysfunction, favors blood stasis and the consequent development of intracardiac thrombosis (ICT) and cardioembolic events. In a study of 116 autopsies of patients with cardiac amyloidosis, conducted at the Mayo Clinic, the presence of ICT was demonstrated in 33% of hearts, with a significantly higher prevalence in patients